BUBekir Ucan

Bekir Ucan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bekir Ucan has a total of 200 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical, hormonal, and treatment outcomes in 247 patients with acromegaly: a single tertiary center experience

    by Ümran Gül, Beki̇r Uçan, Hayri̇ Bostan, Hakan Düğer, Hayri̇ Kertmen, Caner Ünlüer, Hali̇l Durantaş, Oğulcan Boz, Ceren Karaçalik Ünver, Burak Menekşe, et al.

    Background/aim: This study aimed to evaluate the demographic, clinical, and hormonal characteristics; comorbidities; surgical pathology; treatment modalities; and long-term clinical outcomes of patients diagnosed with and managed for acromegaly at our tertiary referral center over a 15-year period. Materials and methods: Between 2010 and 2024, 247 patients with acromegaly were evaluated. Diagnosis and biochemical remission were determined according to the 2024 Acromegaly Consensus Criteria. Results: The median follow-up duration was 8 years (IQR: 3–14). At the time of diagnosis, the most frequent pituitary hormone deficiency was secondary adrenal insufficiency, present in 17.8% of patients. The most common comorbidities were hypertension (HT, 42.1%) and diabetes mellitus (DM, 30.8%). At the time of diagnosis, macroadenomas were present in 153 of 193 patients (79.3%), and, according to the Knosp classification, 28.6% of tumors were grade 4. A total of 218 patients underwent surgical intervention; 86 (39.4%) achieved postoperative cure without the need for adjuvant medical therapy or radiotherapy. Postoperatively, one or more anterior pituitary hormone deficiencies were found in 34 patients (22.8%), with central hypothyroidism being the most common (52.9%). Patients who achieved biochemical remission were significantly older (p = 0.003), had a higher prevalence of HT and DM (both p < 0.05), and were more likely to exhibit positive growth hormone (GH) immunostaining (p = 0.017). In contrast, those who did not achieve remission were more likely to have higher Knosp grades (3–4) (p = 0.002). Conclusions: In this study, a favorable prognosis was associated with older age at diagnosis, lower baseline GH levels, positive GH immunostaining, smaller tumor size, and lower Knosp grade, underscoring the prognostic value of both biochemical and anatomical parameters. Further studies are warranted to refine prognostic markers and establish standardized treatment algorithms to improve long-term outcomes in acromegaly.

  • Open Access

    Identification of High-Risk Individuals for Osteoporosis and Fragility Fractures in Cushing’s Syndrome: A Promising Predictive Approach

    by Enes Ucgul, Burak Menekse, Ogulcan Boz, Huseyin Demirci, Bekir Ucan, Erman Cakal, Takako Araki, Muhammed Kizilgul

    Background: Cushing’s syndrome (CS) causes excessive cortisol exposure, leading to significant skeletal complications. However, there is no validated, CS-specific model to predict osteoporosis and fracture risk. This study aimed to identify independent predictors and develop a practical clinical scoring system. Methods: A retrospective study was conducted on 139 patients with CS diagnosed between 2014 and 2025. Demographic, clinical, and biochemical data were analyzed. Osteoporosis was defined using dual-energy X-Ray absorptiometry criteria. Logistic regression analyses identified independent predictors, and the Cushing-Related Osteoporosis Risk Estimation (CORE) Score was constructed from normalized beta coefficients of significant variables. Results: Osteoporosis was present in 35.9% and fragility fractures in 13.4% of patients. Independent predictors included age ≥ 51 years, symptom duration ≥ 13.5 months, diabetes mellitus, late-night salivary cortisol ≥ 0.42 μg/dL, and midnight serum cortisol ≥ 10.25 μg/dL (all p < 0.05). The CORE Score (0–6 points) showed strong diagnostic performance for osteoporosis (AUC 0.827; sensitivity 88%, specificity 72%) and fractures (AUC 0.866; sensitivity 84%, specificity 78%). Each one-point increase in the CORE Score elevates the risk of osteoporotic fracture by 3.13 times (p < 0.001). Conclusions: The CORE Score represents a promising disease-specific tool for early identification of CS patients at increased risk of osteoporosis and fragility fractures, enabling more personalized management and follow-up strategies, such as prioritizing bone-protective interventions and closer skeletal monitoring. Early identification of high-risk individuals may also facilitate timely therapeutic interventions, potentially reducing future fracture risk.

  • Open Access

    Effect of Intraoperative Nerve Monitorization on Predicting Vocal Cord Paralysis in Thyroid Surgery

    by Başak Yalçıner, Ömer Bayır, Muhammed Kızılgül, Bekir Uçan, Güleser Saylam, Emel Çadallı Tatar, Erman Çakal, Sibel Alicura Tokgöz, İlker Akyıldız, Mehmet Hakan Korkmaz

    Recurrent laryngeal nerve (RLN) paralysis is a distressing complication of thyroidectomy, and many methods have been investigated for prevention. The aim of our study is to investigate to what extent intraoperative neuromonitoring (IONM) predicts postoperative RLN paralysis and what factors may be causing it. Patients who underwent thyroidectomy in our clinic between January 2014 and December 2020 were included. Patient diagnoses, demographic characteristics, laboratory and imaging results, surgical information, and IONM results were evaluated. Data from 287 patients and 523 RLNs were evaluated. Twenty-two (4.2%) of the RLNs were paralytic. The rate of paralysis was significantly higher in total thyroidectomies than in lobectomies (p = 0.046), permanent paralysis rate was higher in left RLNs. Malignancy was statistically associated with permanent paralysis (p = 0.017). The rate of overall and permanent paralysis was higher in patients with negative results of first, second response, first, and second laryngeal twitch examinations. The means of the first and second responses of the paralyzed RLNs were lower (p = 0.016, p < 0.01, respectively). The sensitivity of the IONM increased when the new thresholds of the first and second responses were determined to be 155 and 170 µv, respectively, by ROC analysis. This study demonstrates that voltage variation and magnitude obtained from IONM can be predictive and sensitivity can be increased by using a threshold higher than 100 µV and patients in this range may be at risk for RLN paralysis. Our results may guide future studies of IONM and risk scoring systems to be developed for RLN paralysis.

  • Open Access

    The impact of hypophosphatemia on biochemical profile and renal outcomes in primary hyperparathyroidism: a nationwide retrospective study

    by Nai̇m Ata, Beki̇r Uçan, Hali̇l Durantaş, Oğulcan Boz, Mustafa Şahi̇n, Mustafa Mahi̇r Ülgü, Şuayi̇p Bi̇rİnCi̇, Muhammed Kizilgül

    Background/aim: Although low phosphorus (P) concentrations are a recognized feature of primary hyperparathyroidism (PHPT), they are not among the diagnostic or surgical criteria. The present study evaluates the association between serum phosphorus levels and clinical outcomes in PHPT patients. Materials and methods: A search of the Turkish Ministry of Health’s National Electronic Database was conducted using ICD-10 diagnostic codes and laboratory data to identify PHPT cases within the Turkish population from 2017 to 2022. Results: The records of a total of 113,330 PHPT patients (77.5% female; mean age 58.9 ± 15.6 years) were analyzed, revealing a mean serum phosphorus level of 3.24 ± 0.79 mg/dL. Patients with nephrolithiasis, vitamin D <20 μg/L, and calcium ≥11.4 mg/dL had significantly lower phosphorus levels (p<0.0001). Hypophosphatemia (HypoP) (P < 2.5 mg/dL) was present in 14.3% of patients and was associated with higher parathyroid hormone, calcium, and alkaline phosphatase levels, and lower vitamin D levels (all p < 0.0001). HypoP independently increased the risk of kidney stone formation (OR = 1.53; 95% CI 1.46–1.61). Conclusion: HypoPis associated with more severe biochemical abnormalities and a greater prevalence of nephrolithiasis in PHPT. In regions where vitamin D deficiency is common, low phosphorus levels may indicate more severe diseases, and so routine phosphorus monitoring should be considered as part of PHPT management.


  • Open Access

    Clinical characteristics of Graves’ disease following COVID-19 infection or vaccination: a multicenter case-control study

    by Asena Gökçay Canpolat, Kemal Ağbaht, Ati̇lLa Hali̇l Elhan, Mustafa Cesur, Zi̇yNet Alphan Uç, Seçki̇n Akçay, Hülya Iliksu Gözü, Mehmet Aşik, Hayri̇ Bostan, Beki̇r Ucan, et al.

    Background/aim: To describe Graves’ Disease (GD) associated with COVID-19 infection (COVID) or its vaccines (VAC) and to compare the clinical presentations, laboratory parameters, and short-term clinical course of the disease among different etiology groups (COVID, VAC, and GD control). Materials and methods: Included in this multicenter matched case–control, retrospective cohort study were 239 patients with newly diagnosed (n = 196) or recurrent GD (n = 43) associated with COVID (n = 79) or VAC (n = 160). Each case was matched (1:1) with a control who had been diagnosed with GD prior to COVID. Results: The median age of the entire group was 42 years (female:male = 137:102). Both the COVID (4.6-fold) and VAC (4.1-fold) groups demonstrated higher TSH receptor antibody (TRAb) titers (p < 0.001) compared with the control group (3.5-fold), as well as a higher proportion of recurrent cases. At baseline, the COVID group had higher free triiodothyronine (fT3) levels than the other groups. Graves orbitopathy (GO) was observed in 60 patients (12.6%), with a higher frequency in classical GD (18.4%). At baseline, the variables associated with thyrotoxicosis severity (defined as fT3 levels) were younger age, higher thyroid gland volume (TGV), and etiology, with the COVID and, to a lesser extent, VAC groups presenting with higher fT3 levels. The variables associated with GO were higher TGV, TRAb titers, and smoking, while no association with etiology was identified. Conclusion: The clinical course was similar in all groups other than in some laboratory findings. Although the frequency of GO associated with COVID and VAC was lower, the proportion of cases with a Clinical Activity Score of ≥3 was higher compared to GD. This pattern suggests a potentially stronger immunologic trigger in these cases.


  • Clinicopathological predictors of central lymph node metastasis in clinically node-negative papillary thyroid carcinoma: a retrospective cohort analysis

    by Davut Sakız, Murat Çalapkulu, Muhammed Erkam Sencar, İlKnur Öztürk Ünsal, Mehmet Zabıt Kartal, Bekir Uçan, Erman Çakal

    Purpose This retrospective cohort study aimed to identify clinicopathological predictors of central lymph node metastasis (CLNM) in patients with papillary thyroid carcinoma (PTC). Methods A total of 503 patients with PTC who underwent thyroidectomy with central lymph node dissection were included. Preoperative clinical data, ultrasonographic features, and postoperative histopathological characteristics were analyzed. Results CLNM was detected in 209 (41.55%) patients. Male sex (odds ratio [OR] = 3.12, 95% CI: 1.82–5.35), irregular nodule borders (OR = 2.02, 95% CI: 1.25–3.26) and higher risk categories in the American Thyroid Association (ATA) ultrasonographic pattern stratification system (OR = 13.312, 95% CI: 8.623–20.551) were identified as independent preoperative predictors of CLNM. A simplified model incorporating only the ATA ultrasonographic pattern stratification system and male sex achieved 83.5% accuracy in predicting CLNM. Histopathological evaluation revealed lymphovascular invasion (OR = 4.61, 95% CI: 2.81–7.55), extrathyroidal extension (OR = 2.41, 95% CI: 1.52–3.83), and multifocality (OR = 1.58, 95% CI: 1.04–2.40) as independent predictors of CLNM, while lymphocytic thyroiditis (OR = 0.59, 95% CI: 0.39–0.89) was a protective factor. Conclusion This study establishes that ATA ultrasonographic suspicion patterns combined with the male sex provide an accurate and simplified model for preoperative CLNM prediction in PTC, outperforming complex nomograms. Key independent predictors included male sex, irregular nodule margins, ATA high-risk patterns, lymphovascular invasion, extrathyroidal extension, and multifocality, while lymphocytic thyroiditis was protective. According to the current study, risk assessment and personalized management should favor a holistic approach, rather than focusing solely on individual risk factors.

  • Open Access

    Serum selenium levels and subacute thyroiditis: associations with disease course and long-term outcomes in a case-control study

    by Davut Sakız, Murat Çalapkulu, Muhammed Erkam Sencar, İlKnur Öztürk Ünsal, Sema Hepşen, Hayri Bostan, Bekir Uçan, Erman Çakal

    Background: Subacute thyroiditis (SAT) is an inflammatory disease that induces thyrotoxicosis. Selenium is an essential trace element in thyroid physiology, which has anti-inflammatory and antioxidant properties. However, the relationship between serum selenium levels and SAT has not been well studied. The objective of this study was to evaluate serum selenium levels in patients with SAT compared to healthy controls and to investigate potential correlations between selenium status and clinical outcomes, including disease severity, delayed remission, recurrence, and the development of permanent hypothyroidism. Methods: This case-control study included 59 patients with SAT and 50 healthy control subjects. Serum selenium levels were analysed using inductively coupled plasma mass spectrometry. Results: The serum selenium levels of patients with SAT were 69.10 (24.60–130.20) µg/L, while those of the control group were 64.20 (39.21–106.80) µg/L (p = 0.121). A negative correlation was detected between serum selenium levels and erythrocyte sedimentation rate, C-reactive protein, neutrophil-to-lymphocyte ratio, free thyroxine, and pain severity. Serum selenium levels did not significantly differ in terms of the response to initial treatment, recurrence, and permanent hypothyroidism. Conclusion: The study results showed no significant difference in serum selenium levels between patients with SAT and the control group. These results suggest that although lower serum selenium levels may be associated with a more severe and painful SAT course, there is no impact on the long-term prognosis.

  • Open Access

    Effects of vitamin d replacement combined with Graves’ disease therapy: a retrospective cohort study

    by Beyza Taşkent Sezgi̇n, Muhammed Kizilgül, Özgür Özçeli̇k, Taner Demi̇rCi̇, Hayri̇ Bostan, Ümran Gül, Beki̇r Uçan

    Background/aim: In Graves’ disease (GD), an autoimmune disease, antibodies targeting the TSH receptor cause the production of excessive amounts of thyroid hormone. A significant association has been reported between low 25(OH) Vitamin D3 (VitD) levels and various autoimmune disorders. Therefore, this study aimed to investigate the effects of VitD deficiency and replacement therapy on laboratory and clinical parameters in GD patients.Methods:Fourty GD and 37 healthy control patients were included in this study. Patients with GD were divided into two groups, and the first group was given only antithyroid treatment (n:18), and the second group was given antithyroid treatment plus VitD replacement (n:22). Clinical and laboratory data of all participants were compared at the time of diagnosis and 3 months after treatment.Results: Baseline serum VitD levels in patients with GD were significantly lower than the baseline serum VitD levels of the control group (16.1±9.9 ng/ml vs 22.2±8.5 ng/ml, p <0.005). A significant improvement was observed in serum VitDlevels in patients with GD who received VitD replacement therapy after three months (14.6±8.3 ng/ml vs 40.4±17.2 ng/ml, p<0.001). A significant increase in serum TSH levels and a significant decrease in serum fT3 and fT4 levels were observed at the end of three months in patients with GD who received both antithyroid treatment and antithyroid plus VitD replacement. However, no significant effect of VitD replacement on serum TSH, fT3 and fT4 values was determined.There was no difference in serum TRAb levels between the groups that received and did not receive VitD replacement.Conclusion:Although VitD deficiency was detected in GD patients, no significant accelerating effect of VitD replacement on thyroid hormone levels was observed. Our results need to be confirmed with studies with larger patient numbers and longer follow-up periods.


  • Importance of Hypomagnesemia in Primary Hyperparathyroidism: A Turkish Nationwide Retrospective Cohort Study

    by Bekir Ucan, Naim Ata, Muhammed Kizilgul, Rifat Bozkus, Suayip Birinci

    Patients with primary hyperparathyroidism (PHPT) are predisposed to hypomagnesemia as well as hypophosphatemia. In the current literature, scarce data was available on the clinical significance of hypomagnesemia in PHPT. The present study aimed to investigate the prevalence of hypomagnesemia and its association with complications of PHPT in a large nationwide cohort. A nationwide population-based retrospective study was conducted using anonymized data from the Turkish Ministry of Health National Electronic Database (E-nabız). The International Statistical Classification of Diseases and Related Health Problems (ICD)-10 codes were used to identify patient cohort with PHPT (E21) and 96,337 patients with PHPT were reviewed. Female patients (74,650 (77.488%)) comprised the vast majority of the cohort and the mean age was 58.3 ± 15.3 years. It was observed that 38,709 (40.181%) of the patients had osteoporosis and 11,153 (11.577%) had renal stones. The prevalence of hypomagnesemia was 23.783%. While the frequency of osteoporosis increased significantly in patients with hypomagnesemia (45.435% vs. 38.541%, p < 0.0001), there was no difference between the two groups in terms of the frequency of renal stones. In terms of its possible effects on the presence of hypomagnesemia, the presence of osteoporosis, hypercalcemia (≥ 11.2 mg/dL), lower eGFR levels (< 60 mL/min), higher PTH levels (≥ 150 pg/mL), and advanced age (≥ 50 years) were found to be significantly effective in multivariate logistic regression analyses. Hypomagnesemia is observed in approximately one-quarter of patients with PHPT. The presence of hypomagnesemia in a PHPT patient may indicate a more severe form of hyperparathyroidism and an increased risk of osteoporosis.